Pipeline

STIMOXYGEN

Lead Product: SGEN-33 – Supercharging Radiotherapy for Cancer Patients

SGEN-33 is our pioneering oxygen-generating nanoparticle designed to significantly enhance the effectiveness of radiotherapy. Tumor hypoxia, a condition where tumors are deprived of adequate oxygen, renders traditional radiotherapy up to 300% less effective. Our innovative solution, SGEN-33, directly addresses this challenge by increasing oxygen levels within the tumor microenvironment, thereby amplifying the therapeutic effects of radiotherapy.

Key Features and Benefits:

Oxygen Generation: SGEN-33 releases oxygen directly into hypoxic tumor regions, making radiotherapy more effective.
Intravenous Administration: SGEN-33 is administered intravenously, ensuring easy integration into existing clinical workflows without the need for invasive procedures.
Versatile Application: Effective across various cancer types, including highly resistant and aggressive forms like pancreatic cancer.
Combination Potential: When combined with immunotherapy, SGEN-33 addresses both tumor hypoxia and immunosuppression, making previously untreatable cancers, such as pancreatic cancer, more responsive to treatment.

Current Status:

Preclinical Studies: Robust preclinical data demonstrate the efficacy and safety of SGEN-33 in enhancing radiotherapy in breast, prostate, and pancreatic cancer models.
Toxicology Studies: Comprehensive toxicology studies have been conducted, showing no significant adverse effects, paving the way for clinical trials.
Regulatory Progress: We are actively engaging with regulatory bodies, including the FDA and MHRA, to prepare for Phase I clinical trials.

Next Steps:

Good Laboratory Practice (GLP) Preclinical Trials: These trials are currently underway to further validate the safety and efficacy of SGEN-33.
Phase I Clinical Trial: Upon successful GLP trials, we will commence Phase I clinical trials to assess safety and preliminary efficacy in humans.
Strategic Partnerships: We are forming collaborations with leading pharmaceutical companies and research organizations to accelerate the development and commercialization of SGEN-33.
Future Developments

Expanding the Scope of SGEN-33

While our primary focus is on leveraging SGEN-33 to enhance radiotherapy, we recognize the broader potential of our technology. The unique capabilities of our oxygen-generating nanoparticles open avenues for future pipeline development, including:

Additional Payloads: Exploring the incorporation of therapeutic agents within SGEN-33 nanoparticles to create multifunctional treatment options.
Immunotherapy Combinations: Investigating further combinations with immune checkpoint inhibitors (ICIs) to enhance the immune system’s response to various cancers.

Commitment to Innovation:

At StimOxyGen, our mission is to transform the landscape of cancer treatment through continuous innovation. By harnessing the power of oxygen, we aim to improve patient outcomes and extend survival rates, ultimately making a profound impact on the fight against cancer.

Stay Connected:

Follow our journey and stay updated on our progress as we advance our groundbreaking therapies. Together, we can make a significant difference in the lives of cancer patients worldwide.